AccScience Publishing / JCTR / Volume 7 / Issue 6 / DOI: 10.18053/jctres.07.202106.013
CASE STUDY

Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate

Sjoerd I. P. J. de Faber1,2 Pim G. N. J. Mutsaers3 Martin J. van den Bent1 Matthijs van der Meulen1,4*
Show Less
1 Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Centre Rotterdam, Rotterdam, The Netherlands
2 Department of Neurology, Haga Hospital, The Hague, The Netherlands
3 Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands
Submitted: 22 September 2021 | Revised: 6 November 2021 | Accepted: 12 November 2021 | Published: 29 November 2021
© 2021 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Background and Aim: We present a case of a 22-year-old male diagnosed with B-cell acute lymphoblastic leukemia who received intrathecal (IT) methotrexate (MTX) in addition to his systemic chemotherapy regime. During induction treatment, he presented with a rapidly progressive bilateral paresis, anarthria, and respiratory insufficiency requiring intubation. The brain magnetic resonance imaging showed bilateral lesions with diffusion restriction of the corona radiata/centrum semi-ovale without other abnormalities. He recovered spontaneously without neurological sequelae. The clinical course combined with the radiological findings is suspect for an IT-MTX-induced leukoencephalopathy.
Relevance for Patients: Although neurological deficits after IT-MTX are rare and in most cases selflimiting, it should be recognized as a cause for rapid neurological decline after excluding other causes.

Keywords
methotrexate
leukoencephalopathy
neurotoxicity
acute lymphoblastic leukemia
Conflict of interest
The authors declare no conflicts of interest.
References

[1] Surapaneni UR, Cortes JE, Thomas D, O’Brien S, Giles FJ, Koller C, et al. Central Nervous System Relapse
in Adults with Acute Lymphoblastic Leukemia. Cancer 2002;94:773-9.
[2] Larson RA. Managing CNS Disease in Adults with Acute Lymphoblastic Leukemia. Leuk Lymphoma 2018;59:3-13.
[3] Cohen IJ. Defining the Appropriate Dosage of Folinic Acid after High-Dose Methotrexate for Childhood Acute Lymphatic Leukemia that will Prevent Neurotoxicity Without Rescuing Malignant Cells in the Central Nervous System. J Pediatr Hematol Oncol 2004;26:156-63. 
[4] Brugnoletti F, Morris EB, Laningham FH, Patay Z, Pauley JL, Pui CH, et al. Recurrent Intrathecal Methotrexate
Induced Neurotoxicity in an Adolescent with Acute Lymphoblastic Leukemia: Serial Clinical and Radiologic
Findings. Pediatr Blood Cancer 2009;52:293-5.
[5] Cruz-Carreras MT, Chaftari P, Shamsnia A, GuhaThakurta N, Gonzalez C. Methotrexate-Induced Leukoencephalopathy Presenting as Stroke in the Emergency Department. Clin Case Rep 2017;5:1644-8.
[6] Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible Acute Methotrexate Leukoencephalopathy: Atypical Brain MR Imaging Features. Pediatr Radiol 2006;36:205-12.

Share
Back to top
Journal of Clinical and Translational Research, Electronic ISSN: 2424-810X Print ISSN: 2382-6533, Published by AccScience Publishing